Understanding Tesamorelin
Tesamorelin is a synthetic GHRH analog that stimulates the body’s growth hormone pathway. Its approved use is specific to excess abdominal fat associated with HIV lipodystrophy. Research involving other body-composition goals should be interpreted separately.
Peptide Type
Synthetic growth hormone-releasing hormone (GHRH) analog.
Primary Mechanism
Stimulates the pituitary growth hormone pathway.
Approved Indication
Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Administration Route
Subcutaneous injection in approved product formulations.
Research Context
Visceral fat reduction, body composition and liver-fat research.
Important Distinction
Tesamorelin is not approved as a general weight-loss treatment. Reduction in visceral fat does not necessarily mean equivalent reduction in total body weight or subcutaneous belly fat.
Important Formulation Notice
Egrifta SV and Egrifta WR have different formulations and dosing instructions. They are not interchangeable. Preparation, storage and administration must follow the exact approved product label.
Tesamorelin Reported Dose Contexts
The reference describes historical and formulation-specific daily subcutaneous dose examples. These are not interchangeable regimens or personal dosing recommendations. Follow the prescribing information for the exact approved product.
SC example
Per administration
Frequency
Daily total
Reported cycle
Historical 2 mg Formulation
2 mg SC daily (historical formulation example)
Once daily
2 mg/day (historical example)
Daily treatment; duration depends on the clinical context.
Egrifta SV
1.4 mg SC daily
Once daily
1.4 mg/day (formulation-specific example)
Daily treatment; follow the approved product instructions.
Egrifta WR
1.28 mg SC daily
Once daily
1.28 mg/day (formulation-specific example)
Daily treatment; follow the approved product instructions.
Historical 2 mg Formulation
Per administration
2 mg SC daily (historical formulation example)
Daily total
2 mg/day (historical example)
Reported cycle
Daily treatment; duration depends on the clinical context.
Per administration
1.4 mg SC daily
Daily total
1.4 mg/day (formulation-specific example)
Reported cycle
Daily treatment; follow the approved product instructions.
Per administration
1.28 mg SC daily
Daily total
1.28 mg/day (formulation-specific example)
Reported cycle
Daily treatment; follow the approved product instructions.
The historical 2 mg example, Egrifta SV 1.4 mg and Egrifta WR 1.28 mg refer to different formulation contexts. SV and WR must not be substituted for one another. The reference also describes clinical research exposure lasting 26 or 52 weeks and up to 12 months in liver-fat research. No dose ramp is described.
Prescription & Formulation Warning
Tesamorelin is a prescription medication. These reported examples are provided for educational comparison only and must not be used to prepare, calculate or administer a dose. Use the exact prescribing information and guidance from a qualified healthcare professional.
Tesamorelin Safety & Considerations
Tesamorelin affects the growth hormone and IGF-1 pathways. Its safety profile requires attention to contraindications, glucose regulation, fluid retention and other treatment-related concerns.
Tesamorelin Storage Guidelines
Egrifta SV
The reference states that the SV formulation should be used immediately after mixing.
Egrifta WR
The FDA-corrected storage information in the reference states 20–25°C and disposal seven days after mixing.
Formulation Compatibility
Egrifta SV and Egrifta WR have different formulation-specific preparation and storage requirements. Their instructions are not interchangeable.
Handling Precaution
Always follow the exact product label for preparation, storage and disposal. Do not apply one formulation’s storage instructions to another.
Tesamorelin Concentration Examples
The reference includes independently recomputed concentration examples for different assumed amounts and final volumes. These calculations are mathematical examples only, not mixing or administration instructions.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
U refers to a U-100 volume marking, where 1 U equals 0.01 mL. The reference also lists 5 mg/1 mL, 5 mg/2.5 mL, 10 mg/2 mL and 10 mg/5 mL calculation examples. These values are not preparation or injection instructions. Always use the exact approved product information.
Tesamorelin Clinical Research Findings
Clinical research has examined tesamorelin in adults with HIV-associated lipodystrophy and in separate liver-fat research settings. Results should be interpreted according to the population, study duration and measured endpoint.
Phase 3 HIV-Lipodystrophy Trials
Two Phase 3 trials in adults with HIV-associated lipodystrophy reported reductions in visceral adipose tissue.
Visceral Fat Reduction
The reference reports visceral-fat reductions of approximately 15.2% and 11.7% at 26 weeks across the two Phase 3 trials.
Liver-Fat Research
Separate research examined liver-fat outcomes with exposure periods of 26 or 52 weeks and up to 12 months. These findings should not be interpreted as proof of general weight-loss effectiveness.
Tesamorelin Approval & Research Status
Specific Approved Indication
Tesamorelin has an approved use for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. This approval does not establish general weight-loss use or approval for all body-composition goals. Egrifta SV and Egrifta WR have formulation-specific instructions and are not interchangeable.
This page is for educational and research-reference purposes only. It is not medical advice, a prescription or an administration guide. Always consult the current approved product label and a qualified healthcare professional.
